메뉴 건너뛰기
Clinical Breast Cancer
Volumn 8, Issue 3, 2008, Pages 285-286
Severe thrombocytopenia induced by a single infusion of trastuzumab
Author keywords

HER2; Lymphadenopathy; Petechial rash; Tamoxifen
Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; HEPARIN; IMMUNOGLOBULIN G; TAMOXIFEN; TRASTUZUMAB;
EID: 46949105873     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.034     Document Type: Article
Times cited : (15)
References (8)
  • 1
    • 84898692945 scopus 로고    scopus 로고
    • National Institute for Clinical Medicine. Technology Appraisal Guidance No. 34: Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast cancer. London, UK. March 2002.
    • National Institute for Clinical Medicine. Technology Appraisal Guidance No. 34: Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast cancer. London, UK. March 2002.
  • 2
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 3
    • 33845914783 scopus 로고    scopus 로고
    • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. The HERA study team
    • Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The HERA study team. Lancet 2007; 369:29-36.
    • (2007) Lancet , vol.369 , pp. 29-36
    • Smith, I.1    Procter, M.2    Gelber, R.D.3
  • 4
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84.
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 5
    • 84898689569 scopus 로고    scopus 로고
    • Summary of product characteristics: Herceptin® and Roche. Data on file. Basel, Switzerland
    • Summary of product characteristics: Herceptin® and Roche. Data on file. Basel, Switzerland.
  • 6
    • 0032948845 scopus 로고    scopus 로고
    • Drug-induced immune thrombocytopenia: An overview of pathogenesis
    • Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999; 36:2-6.
    • (1999) Semin Hematol , vol.36 , pp. 2-6
    • Aster, R.H.1
  • 7
    • 33847388520 scopus 로고    scopus 로고
    • Drug-induced immune-mediated thrombocytopenia-from purpura to thrombosis
    • Warkentin TE. Drug-induced immune-mediated thrombocytopenia-from purpura to thrombosis. N Engl J Med 2007; 356:891-3.
    • (2007) N Engl J Med , vol.356 , pp. 891-893
    • Warkentin, T.E.1
  • 8
    • 0032403959 scopus 로고    scopus 로고
    • Drug-induced thrombocytopenia: A systematic review of published case reports
    • George JN, Raskob GE, Shah S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129:886-90.
    • (1998) Ann Intern Med , vol.129 , pp. 886-890
    • George, J.N.1    Raskob, G.E.2    Shah, S.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.